News | April 03, 2022
JBCPL buys Azmarda trademark for India at Rs 246 crore
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
The organization has introduced an advanced FlashMicelle technology which is a combination of ultra-rapid mixing techniques, and a uniquely powerful approach to modify the structure of oil-based formulations to improve their therapeutic efficacy substantially
This state-of-art technology will help pulmonologists to diagnose lung cancer in the very early stages helping the patient get an early surgical resection
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
It is one of the 15 medical device manufacturers approved under the government’s PLI scheme
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Bayer will be setting up 27 telemedicine centres in 12 districts across 8 states with implementing partners Telerad RxDx and Piramal Swasthya
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Subscribe To Our Newsletter & Stay Updated
